Starpharma Holdings Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SPHRF research report →
Price Chart
About the company
Starpharma Holdings Limited is a global biopharmaceutical firm dedicated to the investigation, advancement, and marketing of its proprietary dendrimer-based products for pharmaceutical, life science, and other diverse applications. Among its commercialized offerings is VivaGel, an antibiotic-free therapy designed for both preventing and managing bacterial vaginosis. The company's pipeline also features the VivaGel antiviral condom and VIRALEZE, an antiviral nasal spray.
- CEO
- Cheryl Maley
- IPO
- 2007
- Employees
- 50
- HQ
- Abbotsford, VIC, AU
Get TickerSpark's AI analysis on SPHRF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- Market Cap
- $244.14M
- P/E
- -48.83
- Fwd P/E
- 128.13
- PEG
- 0.36
- P/S
- 29.17
- P/B
- 26.19
- EV/EBITDA
- -18.62
- Div Yield
- 0.00%
- Gross Margin
- 86.26%
- Op Margin
- -159.60%
- Net Margin
- -61.95%
- ROE
- -42.35%
- ROIC
- -52.98%
Latest fiscal year · YoY change
- Revenue
- $12.03M+145.0%
- Gross Profit
- $10.38M+181.4%
- Op Income
- $-19,205,052
- Net Income
- $-7,454,540+25.4%
- EPS
- $-0.02+27.6%
- OCF Growth
- +52.6%
- FCF Growth
- +48.7%
- 52W High
- $0.58
- 52W Low
- $0.16
- 50D MA
- $0.50
- 200D MA
- $0.41
- Beta
- 0.77
- RSI (14)
- 92
- Avg Volume
- 40
No earnings-call transcripts are available for SPHRF yet.
- Free Float
- 69.9%
- Shares Outstanding
- 420.93M
- Float Shares
- 294.02M
Our SPHRF coverage
Recent articles, reports, and earnings notes.
No research on SPHRF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SPHRF report →